N-Acetyl Selank Amidate

N-Acetyl Selank Amidate is a stabilized synthetic heptapeptide with the sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2, derived from the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) fused to a C-terminal Pro-Gly-Pro extension. The parent compound selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has an approximate molecular weight of 750 Da. The N-acetyl and C-amide modifications increase resistance to exo- and endopeptidases, extending the biological half-life from approximately 1-3 minutes for native selank to an estimated 15-20 minutes and improving central nervous system penetration.

The primary mechanism of action involves allosteric modulation of GABA-A receptors. Selank increases the sensitivity of the GABA binding site on the alpha subunit without directly activating the receptor, as confirmed by electrophysiology studies on hippocampal neurons. This produces anxiolysis without the sedation, amnesia, or dependence that characterize direct GABA-A agonists such as benzodiazepines. The allosteric mechanism means GABA-A signaling is enhanced only when endogenous GABA is present, preserving normal inhibitory tone rather than overriding it.

Beyond GABA modulation, selank exerts cognitive-enhancing effects through multiple parallel pathways. It increases BDNF mRNA expression in the hippocampus, as confirmed in slice preparations using in situ hybridization. It inhibits enkephalin-degrading enzymes (enkephalinase/neprilysin), raising endogenous enkephalin levels that contribute to stress resilience and emotional regulation. It also stabilizes the turnover of monoamines in the prefrontal cortex: dopamine, norepinephrine, and serotonin levels are normalized rather than simply elevated, which may explain why selank improves cognitive flexibility without producing the jitteriness associated with stimulants.

Clinical research in Russia led to selank receiving regulatory approval as an anxiolytic nasal spray. In controlled clinical trials involving patients with generalized anxiety disorder, selank reduced Hamilton Anxiety Scale (HAM-A) scores by 30-40% over 14 days of intranasal administration. Importantly, no cognitive impairment was observed on any neuropsychological measure; several studies reported improved attention and working memory during anxiolytic treatment. A 6-month follow-up study found no evidence of tolerance, physical dependence, or withdrawal symptoms upon discontinuation.

Pharmacokinetically, intranasal administration delivers selank to the brain via the olfactory nerve and trigeminal pathways within 5-10 minutes. The N-acetyl selank amidate form achieves higher and more sustained brain tissue levels compared to unmodified selank. Systemic bioavailability via the nasal route is estimated at 15-25%. The peptide is metabolized by tissue peptidases into inactive fragments that are cleared renally.

Storage recommendations: store lyophilized powder at -20C for long-term stability or 2-8C for up to 60 days. Reconstituted nasal solutions should be kept at 2-8C and used within 4-6 weeks. The peptide is stable across a pH range of 4-7 in aqueous solution. Protect from light and avoid repeated freeze-thaw cycles to maintain potency.

The safety profile of selank is well-established through Russian regulatory review and post-marketing surveillance. No serious adverse events have been reported in clinical trials or post-approval monitoring. The most common side effect is mild transient nasal discomfort with intranasal administration. No hepatotoxicity, nephrotoxicity, or cardiovascular effects have been observed. Selank does not interact with alcohol or other CNS depressants in the manner that benzodiazepines do, and it does not impair motor coordination or reaction time at therapeutic doses.

The combination of anxiolysis with cognitive enhancement is exceptionally rare among pharmacological agents. Most anxiolytics impair cognition; selank improves it. This dual profile makes it particularly relevant for research into performance under stress, where both anxiety reduction and preserved cognitive function are desired outcomes.